Loading...
•
Sep 30, 2024
Leap Therapeutics Q3 2024 Earnings Report
Leap Therapeutics reported financial results for the third quarter ended September 30, 2024.
Key Takeaways
Leap Therapeutics reported a net loss of $18.2 million for the third quarter of 2024, compared to a net loss of $13.7 million for the same period in 2023. Research and development expenses increased to $14.9 million, and the company's cash and cash equivalents totaled $62.8 million as of September 30, 2024.
Completed enrollment in the expanded Part B of the Phase 2 DeFianCe study of DKN-01 in patients with advanced colorectal cancer.
Initial randomized controlled data from the DisTinGuish study and the DeFianCe study is expected in the coming months.
FL-501 is moving into development based on positive preclinical data.
Cash position is expected to fund operations into Q2 2026.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...